Get the Stockscreener App
0.92
3.70%
-0.025
Polyrizon Ltd stock is traded at $0.92, with a volume of 4,709.
It is down -3.70% in the last 24 hours and up +0.00% over the past month.
Polyrizon Ltd is a clinical development stage biotech company specializing in the development of nasal gels to provide preventative treatment to protect against a wide cross-section of viruses, including certain variants of COVID-19 that are also considered to cause more infections and spread faster than the original strain of the virus (the CDC expects that additional variants of the virus will continue to occur), influenza, allergens, and other toxins. Its technology platforms are Capture & Contain and Trap & Target.
See More
Previous Close:
$0.945
Open:
$0.95
24h Volume:
4,709
Relative Volume:
0.11
Market Cap:
$3.96M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+10.98%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$0.91
$0.95
1-Week Range:
$0.77
$1.0594
52-Week Range:
$0.77
$1.51
Polyrizon Ltd Stock (PLRZ) Company Profile
Compare PLRZ with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| PLRZ | 0.91 | 3.96M | 0 | 0 | 0 | 0.00 |
| VRTX | 445.81 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 735.95 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 584.00 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 247.73 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.25 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Polyrizon Ltd Stock (PLRZ) Latest News
Aegis Capital Corp. Acted as Sole Bookrunner on a $4.2 Million (IPO) Initial Public Offering for Polyrizon Ltd. (NASDAQ: PLRZ) - Quantisnow
PLRZPolyrizon Ltd. Ordinary Shares Latest Stock News & Market Updates - StockTitan
Polyrizon Announces Closing of $4.2 Million Initial Public Offering - The Manila Times
Polyrizon Prices 958.9K Share IPO at $4.38/unit By Investing.com - Investing.com South Africa
Polyrizon Prices 958.9K Share IPO at $4.38/unit - Investing.com
Polyrizon Announces Pricing of $4.2 Million Initial Public Offering and Listing on the Nasdaq Capital Market Under New Ticker 'PLRZ” - The Manila Times
Polyrizon Announces Pricing of $4.2 Million Initial Public Offering and Listing on the Nasdaq Capital Market Under New Ticker “PLRZ” - StockTitan
SciSparc Grants Global Rights for Pain Therapy to Biotech Company in Agreement Worth up to $6 Million - GlobeNewswire
Israel-Based Biotech Penny Stock SciSparc Outlicenses Its Cannabinoid Pain Therapy - Benzinga
SciSparc signs exclusive patent license agreement with Polyrizon - TipRanks
SciSparc Finalizes Exclusive Global Out-Licensing Agreement for its Pain Therapy Valued at $3 million - GlobeNewswire
Israeli biotech Polyrizon discloses terms for proposed $19M US IPO (NASDAQ:MDGS) - Seeking Alpha
Polyrizon Ltd Stock (PLRZ) Financials Data
There is no financial data for Polyrizon Ltd (PLRZ). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):